nanotech investing Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
nanotech investing Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
nanotech investing Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome
nanotech investing Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
nanotech investing Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
nanotech investing Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
nanotech investing Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome , a Rare Pediatric Congenital Heart Defect
nanotech investing Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
nanotech investing George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
nanotech investing Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
Juggernaut Exploration Announces Bought Deal Private Placement Structured Flow-Through Financing for Gross Proceeds of C$10M
Juggernaut Exploration Announces Bought Deal Private Placement Structured Flow-Through Financing for Gross Proceeds of C$10M
